ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
First drug approved for seborrheic dermatitis with a new mechanism of action in over two decades available in pharmacies this weekEffective, safe, and very well-tolerated steroid-free foam provides...